We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Liquid Biopsy Solution Enables Non-Invasive Sample Collection and Direct Cell-Free DNA Stabilization from Urine

By LabMedica International staff writers
Posted on 26 Sep 2024
Print article
Image: The PAXgene Urine Liquid Biopsy Set is the first standardized preanalytical workflow that stabilizes cell-free DNA in urine for subsequent analysis (Photo courtesy of PreAnalytiX)
Image: The PAXgene Urine Liquid Biopsy Set is the first standardized preanalytical workflow that stabilizes cell-free DNA in urine for subsequent analysis (Photo courtesy of PreAnalytiX)

Urine cell-free DNA (cfDNA) presents significant potential for research and future clinical applications. It facilitates the measurement and analysis of cfDNA fragments, detection of genetic alterations, assessment of methylation status, and generation of genomic data that may not be obtainable from blood samples. However, analyzing urine cfDNA has posed challenges, as cfDNA degrades quickly after collection, potentially releasing contaminating genomic DNA. Now, an innovative solution enables non-invasive sample collection and immediate stabilization of cfDNA in urine, making standardized urine sampling practical for clinical use.

PreAnalytiX GmbH (Hombrechtikon, Switzerland), a joint venture between QIAGEN N.V. (Venlo, The Netherlands) and BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), has launched the PAXgene Urine Liquid Biopsy Set. This set enables the reliable analysis of cfDNA from urine using molecular testing technologies such as qPCR, digital PCR, and next-generation sequencing (NGS). The PAXgene Urine Liquid Biopsy Set tackles the challenge of accessing cfDNA in urine by integrating a preservation solution that stabilizes cfDNA at the point of collection. It is the first set to offer a validated, standardized, and comprehensive preanalytical workflow, making urine cfDNA analysis more accessible for research purposes.

The PAXgene Urine Liquid Biopsy Set marks a significant improvement in sample quality, standardization, and ease of use for researchers handling urine samples. It features a closed system for urine collection and cfDNA stabilization, offering flexibility for sample shipment and storage under various conditions. Additionally, it integrates seamlessly into established workflows and is compatible with QIAGEN's industry-leading sample preparation products. Developed in line with Europe’s latest CEN/TS standards for the preanalytical handling of urine cfDNA, the set provides an optimized and standardized workflow.

Urine liquid biopsy has immense potential to aid researchers in detecting minimal residual disease, monitoring treatment responses, and identifying therapeutic targets, complementing blood plasma analysis for a more comprehensive understanding. However, unlike blood samples, there has been a lack of well-established technical solutions for the collection, storage, transport, and processing of urine samples—until now. The PAXgene Urine Liquid Biopsy Set bridges this gap. Commercialized by QIAGEN, the new set complements the company’s broader portfolio of liquid biopsy solutions, which cover various analytes (circulating cell-free nucleic acids, tumor cells, exosomes) and molecular detection technologies (NGS, qPCR, digital PCR), empowering researchers and clinicians to harness the full potential of liquid biopsy across diverse applications.

“With the innovative PAXgene Urine Liquid Biopsy Set, we are excited to address a pressing market need for a urine collection, stabilization, transport and storage device that is integrated into a complete preanalytical workflow for the development of cfDNA-based tests,” said Dr. Uwe Oelmueller, PreAnalytiX Management Committee Co-Chair and Head of MDx Development Sample Technologies at QIAGEN. “Liquid biopsies have huge potential, but accurate results are highly dependent on the workflow. As a result, the stabilization of analyte profiles in samples is critical to ensure that test results are reliable and reproducible."

Related Links:
PreAnalytiX GmbH
QIAGEN N.V.
BD

Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Automated Nucleic Acid Extraction Instrument
EX9600
New
Silver Member
Comprehensive Acute Marker Control for Critical Diagnostics
Seronorm Cardiac Acute Control

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: A scanning electron microscope image of chiral gold nanoparticles developed for a new microfluidic chip (Matter, 2024; DOI: 10.1016/j.matt.2024.09.005)

Simple Blood Draw Helps Diagnose Lung Cancer 10 Times Faster

Once dismissed as cellular waste, exosomes—tiny vesicles released by cells containing proteins, DNA, or RNA fragments—have emerged as vital players in cell-to-cell communication over the past decade.... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.